se ha leído el artículo
array:19 [ "pii" => "X0211699504029833" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2218 "formatos" => array:3 [ "EPUB" => 245 "HTML" => 1569 "PDF" => 404 ] ] "itemSiguiente" => array:15 [ "pii" => "X0211699504029825" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2395 "formatos" => array:3 [ "EPUB" => 236 "HTML" => 1675 "PDF" => 484 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "NADPH Oxidación y stress oxidativo en las enfermedades cardiovasculares" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "4" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. A. CLARK , T. K. EPPERSON , J. VALENTE" "autores" => array:1 [ 0 => array:1 [ "nombre" => "R. A. CLARK , T. K. EPPERSON , J. VALENTE" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029825?idApp=UINPBA000064" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029825/v0_201502091335/en/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699504029841" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:1-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5161 "formatos" => array:3 [ "EPUB" => 241 "HTML" => 4442 "PDF" => 478 ] ] "es" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Introducción</span>" "titulo" => "Introducción" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "2" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. LUÑO" "autores" => array:1 [ 0 => array:1 [ "nombre" => "J. LUÑO" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029841?idApp=UINPBA000064" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029841/v0_201502091335/es/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "¿Es el agente o el nivel de presión arterial lo que influye en la protección renal de las nefropatías crónicas?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "3" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "F. LOCATELLI" "autores" => array:1 [ 0 => array:1 [ "nombre" => "F. LOCATELLI" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 ¿Es el agente o el nivel de presión arterial lo que influye en la protección renal de las nefropatías crónicas? F. Locatelli Department of Nephrology and Dialysis. Ospedale A. Manzoni. Lecco. Italy. Hypertension is not only an important presenting feature of renal disease and, together with proteinuria, probably a major factor contributing to progression, but also a significant determinant of morbidity and mortality among hemodialysis patients. Over the last decade, a number of trials have been performed to assess the degree of BP reduction needed to achieve reno-protection. The results of the Modification of Diet in Renal Disease (MDRD) Study clearly showed that stricter BP control was capable of slowing CRI progression, compared with BP control that was usual for that time. The patients with higher levels of baseline proteinuria received greater benefits from being assigned to a low BP target. Over recent years it has become clear that not all anti-hypertensive agents are equally effective in slowing CKD progression, and that some have an additional reno-protective effect that seems at least partially independent of BP reduction and is probably linked to their capacity of halting some of the pathogenic mechanisms involved in renal damage. Indeed, several clinical trials have shown that drugs blocking the renin-angiotensin system are more effective in reducing CKD progression compared with other anti-hypertensive drugs in diabetic and nondiabetic nephropathies. However, in the majority of large trials, target and achieved BP values were constantly higher than those nowadays recommended. Moreover, the BP values were often lower in the experimental groups (ACE-I or ATIIRA) compared with the control groups and BP values during 24 hours were not recorded. Although this effect seems to be partially independent of blood pressure (BP) reduction, it is still unclear whether these drugs are really superior to other anti-hypertensive agents when the BP values recommended by the present guidelines are actually achieved. This is particularly true when considering that, in published trials, target and achieved blood pressure values were constantly higher than those nowadays recommended. Furthermore, in the majority of these studies, patients treated with ACE-inhibitors (ACE-I) or Angiotensin II receptor antagonists (ATIIRA) achieved lower BP values than those in control groups and BP values during 24 hours were not recorded. A secondary analysis of the AIPRI data, which has taken into account both the effects of SBP and DBP, at baseline and during follow-up, on the risk of developing the primary composite end-point showed that proteinuria values at baseline and throughout follow-up were the main factors related to the renal outcomes (each g per day greater levels of proteinuria at baseline was associated with an increase of 39% in the relative risk for the primary end-point, each g per day greater levels of proteinuria during follow-up was associated with an increase in the relative risk of 35%). DBP at baseline (relative risk increase of 6% for each mmHg increase) and SBP changes from baseline throughout follow-up (relative risk increase of 3% for each mmHg increase) were also independently related to the primary end-points. When all of these co-variates were considered, a trend towards independent reno-protection by ACE-I was still present, but without statistical significance (relative risk reduction of 20%). However, the regression lines of the control and benazepril groups were parallel (P 0.326) and significantly different (P < 0.001), possibly indicating that the anti-proteinuric effect of ACE-I was independent of the BP control achieved. In conclusion, the reno-protective effect of these agents (ACE-I, ATIIRA) is partially independent of a better BP control. However, caution should be paid in attributing true biological reno-protective properties to drugs just basing on statistical adjustments of BP values, although robustly performed, without being aware of what those BP values actually reflect. 3 " "pdfFichero" => "P7-E232-S132-A2962.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029833/v0_201502091335/en/main.assets" "Apartado" => array:4 [ "identificador" => "35393" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Artículos Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029833/v0_201502091335/en/P7-E232-S132-A2962.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029833?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 4 | 8 | 12 |
2024 Octubre | 38 | 27 | 65 |
2024 Septiembre | 36 | 28 | 64 |
2024 Agosto | 54 | 62 | 116 |
2024 Julio | 42 | 28 | 70 |
2024 Junio | 60 | 37 | 97 |
2024 Mayo | 55 | 27 | 82 |
2024 Abril | 36 | 36 | 72 |
2024 Marzo | 28 | 21 | 49 |
2024 Febrero | 40 | 34 | 74 |
2024 Enero | 30 | 20 | 50 |
2023 Diciembre | 26 | 18 | 44 |
2023 Noviembre | 55 | 25 | 80 |
2023 Octubre | 42 | 30 | 72 |
2023 Septiembre | 65 | 29 | 94 |
2023 Agosto | 46 | 27 | 73 |
2023 Julio | 35 | 25 | 60 |
2023 Junio | 31 | 12 | 43 |
2023 Mayo | 49 | 30 | 79 |
2023 Abril | 16 | 16 | 32 |
2023 Marzo | 28 | 21 | 49 |
2023 Febrero | 20 | 36 | 56 |
2023 Enero | 42 | 29 | 71 |
2022 Diciembre | 42 | 39 | 81 |
2022 Noviembre | 30 | 25 | 55 |
2022 Octubre | 31 | 35 | 66 |
2022 Septiembre | 34 | 30 | 64 |
2022 Agosto | 34 | 43 | 77 |
2022 Julio | 31 | 47 | 78 |
2022 Junio | 37 | 36 | 73 |
2022 Mayo | 20 | 42 | 62 |
2022 Abril | 24 | 45 | 69 |
2022 Marzo | 48 | 43 | 91 |
2022 Febrero | 28 | 35 | 63 |
2022 Enero | 30 | 26 | 56 |
2021 Diciembre | 36 | 43 | 79 |
2021 Noviembre | 21 | 35 | 56 |
2021 Octubre | 37 | 45 | 82 |
2021 Septiembre | 24 | 40 | 64 |
2021 Agosto | 23 | 38 | 61 |
2021 Julio | 35 | 33 | 68 |
2021 Junio | 18 | 19 | 37 |
2021 Mayo | 22 | 34 | 56 |
2021 Abril | 57 | 28 | 85 |
2021 Marzo | 31 | 29 | 60 |
2021 Febrero | 24 | 21 | 45 |
2021 Enero | 25 | 21 | 46 |
2020 Diciembre | 17 | 14 | 31 |
2020 Noviembre | 22 | 15 | 37 |
2020 Octubre | 16 | 15 | 31 |
2020 Septiembre | 9 | 10 | 19 |
2020 Agosto | 33 | 8 | 41 |
2020 Julio | 15 | 9 | 24 |
2020 Junio | 16 | 11 | 27 |
2020 Mayo | 31 | 18 | 49 |
2020 Abril | 29 | 20 | 49 |
2020 Marzo | 27 | 16 | 43 |
2020 Febrero | 29 | 14 | 43 |
2020 Enero | 32 | 18 | 50 |
2019 Diciembre | 40 | 23 | 63 |
2019 Noviembre | 37 | 10 | 47 |
2019 Octubre | 24 | 7 | 31 |
2019 Septiembre | 18 | 14 | 32 |
2019 Agosto | 11 | 12 | 23 |
2019 Julio | 19 | 25 | 44 |
2019 Junio | 18 | 10 | 28 |
2019 Mayo | 13 | 22 | 35 |
2019 Abril | 36 | 23 | 59 |
2019 Marzo | 16 | 14 | 30 |
2019 Febrero | 12 | 11 | 23 |
2019 Enero | 20 | 16 | 36 |
2018 Diciembre | 37 | 26 | 63 |
2018 Noviembre | 53 | 10 | 63 |
2018 Octubre | 55 | 19 | 74 |
2018 Septiembre | 30 | 7 | 37 |
2018 Agosto | 23 | 10 | 33 |
2018 Julio | 20 | 10 | 30 |
2018 Junio | 15 | 5 | 20 |
2018 Mayo | 20 | 12 | 32 |
2018 Abril | 21 | 6 | 27 |
2018 Marzo | 16 | 6 | 22 |
2018 Febrero | 18 | 6 | 24 |
2018 Enero | 12 | 5 | 17 |
2017 Diciembre | 27 | 6 | 33 |
2017 Noviembre | 15 | 4 | 19 |
2017 Octubre | 16 | 5 | 21 |
2017 Septiembre | 12 | 5 | 17 |
2017 Agosto | 13 | 7 | 20 |
2017 Julio | 14 | 5 | 19 |
2017 Junio | 8 | 3 | 11 |
2017 Mayo | 11 | 7 | 18 |
2017 Abril | 18 | 3 | 21 |
2017 Marzo | 12 | 4 | 16 |
2017 Febrero | 14 | 6 | 20 |
2017 Enero | 7 | 3 | 10 |
2016 Diciembre | 17 | 4 | 21 |
2016 Noviembre | 13 | 4 | 17 |
2016 Octubre | 10 | 2 | 12 |
2016 Septiembre | 23 | 2 | 25 |
2016 Agosto | 39 | 0 | 39 |
2016 Julio | 56 | 0 | 56 |
2016 Junio | 34 | 0 | 34 |
2016 Mayo | 85 | 0 | 85 |
2016 Abril | 41 | 0 | 41 |
2016 Marzo | 39 | 0 | 39 |
2016 Febrero | 59 | 0 | 59 |
2016 Enero | 60 | 0 | 60 |
2015 Diciembre | 68 | 0 | 68 |
2015 Noviembre | 59 | 0 | 59 |
2015 Octubre | 46 | 0 | 46 |
2015 Septiembre | 33 | 0 | 33 |
2015 Agosto | 32 | 0 | 32 |
2015 Julio | 17 | 0 | 17 |
2015 Junio | 16 | 0 | 16 |
2015 Mayo | 19 | 0 | 19 |
2015 Abril | 7 | 0 | 7 |